- Home
- EDD vs PROK Comparison
EDD vs PROK Comparison
Compare EDD & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EDD | PROK |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 371.9M | 316.0M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | EDD | PROK |
|---|---|---|
| Price | $5.86 | $1.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.40 |
| AVG Volume (30 Days) | 293.4K | ★ 1.1M |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 7.52% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $893,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1075.00 |
| 52 Week Low | $4.96 | $1.30 |
| 52 Week High | $6.18 | $3.48 |
Technical Indicators
Market Signals| Indicator | EDD | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 48.23 | 69.27 |
| Support Level | $5.74 | $1.56 |
| Resistance Level | $6.03 | $2.22 |
| Average True Range (ATR) | 0.08 | 0.11 |
| MACD | -0.01 | 0.05 |
| Stochastic Oscillator | 35.96 | 100.00 |
Price Performance
Historical ComparisonAbout EDD Morgan Stanley Emerging Markets Domestic Debt Fund Inc.
Morgan Stanley Emerging Markets Domestic Debt Fund Inc is a closed-end management investment company. The company's primary investment objective is to seek a high level of current income, with a secondary investment objective of long-term capital appreciation. It seeks to achieve investment objectives by investing, under normal circumstances, at least 80% of its managed assets in emerging markets domestic debt. The fund's portfolio includes sovereign, quasi-sovereign, corporate bonds in emerging markets.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.